G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General Counsel

July 09, 2018 — RESEARCH TRIANGLE PARK, N.C. (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced appointments for two newly created executive leadership roles to support the company’s continued growth. John Demaree joins the company as Chief Commercial Officer and Stillman Hanson has been named General Counsel. Read More

Standard Bariatrics closes Series A round of financing

April 18, 2018 — CINCINNATI, OH — Standard Bariatrics, Inc., an innovator of bariatric surgical devices, has raised a Series A round of financing. RiverVest Venture Partners led the round with participation from Hatteras Venture Partners, Queen City Angels/QCA First Fund V, Emergent Medical Partners, Accelerant Fund and North Coast Angels. The size of the round is undisclosed. Read More

Elligo Health Research Raises $16M to Improve Access to Clinical Trials

March 20, 2018 — AUSTIN, TX (BUSINESS WIRE) — Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients, announced today $16 million in Series B funding led by Hatteras Venture Partners and Noro-Moseley Partners with participation from FS Healthcare LLC, Excelerate Health Ventures and all existing Series A investors including Shumway Capital. Read More

Wildflower Health Receives $8 Million Capital Investment in Funding Round Led by Health Enterprise Partners

March 07, 2018 — SAN FRANCISCO (PRWEB) — Wildflower Health today announced it has secured $8 million in capital investment to advance its mission of growing healthy families. The funding round was led by Health Enterprise Partners, a growth equity firm specializing in healthcare services and information technology whose investors include some of the largest health systems and health plans across the country. Read More

Clearside Announces Pricing of Public Offering of Common Stock

March 07, 2018 — ALPHARETTA, Ga. (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the pricing of its underwritten public offering of 6,538,462 shares of its common stock at a price to the public of $13.00 per share. Read More

G1 Therapeutics Announces Pricing of Offering of Common Stock

March 07, 2018 — RESEARCH TRIANGLE PARK, N.C. (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced the pricing of an underwritten public offering of 3,400,000 shares of its common stock at a public offering price of $29.50, for total gross proceeds of $100.3 million. Read More

Press Ganey Expands Real-Time Data Collection Capabilities Through Acquisition of Bivarus

January 16, 2018 — BOSTON — Press Ganey today announced the acquisition of Bivarus, which offers real-time patient and caregiver insights through a patented, dynamic consumer feedback platform. The addition of Bivarus’s capabilities complements Press Ganey’s comprehensive suite of solutions designed to help clients improve the overall safety, quality and experience of care for consumers and achieve the goal of zero harm. Read More

Qvella Raises US$20M in Series B Financing to Fund Clinical Trials, On-going Research, Team Expansion, and Manufacturing Buildup

December 4, 2017 — TORONTO — Qvella, a leading molecular diagnostics company, today announced it has closed US$20 million in Series B financing. The funding round was co-led by Qvella’s existing investor syndicate—including RA Capital, Whitecap Venture Partners, Hatteras Ventures, and Sands Capital—and new strategic investor bioMérieux, a world leader in the field of in vitro diagnostics. Read More

G1 Therapeutics and AstraZeneca Enter Clinical Trial Collaboration in Non-Small Cell Lung Cancer

Nov. 28, 2017 (GLOBE NEWSWIRE) — RESEARCH TRIANGLE PARK, N.C. — G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced a clinical trial collaboration with AstraZeneca to evaluate AstraZeneca’s epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso® (osimertinib) in combination with G1’s oral CDK4/6 inhibitor G1T38 for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). Read More